Biotech News

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Nkarta (NKTX)Nkarta2026-06-25 13:46 ESTEarnings

Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle Initial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical conference in 2026 Cash balance of $295.1 million on December 31, 2025, including

Open original release

Related news

NKTXNkarta2026-06-25 13:46 EST

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

NKTXNkarta2026-06-25 13:46 EST

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

NKTXNkarta2026-06-25 13:46 EST

Nkarta to Participate in a September Investor Conference

NKTXNkarta2026-06-25 13:46 EST

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

NKTXNkarta2026-06-25 13:46 EST

Nkarta to Participate in November Investor Conferences

NKTXNkarta2026-06-25 13:46 EST

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

NKTXNkarta2026-06-25 13:46 EST

Nkarta to Participate in Evercore Healthcare Conference

NKTXNkarta2026-06-25 13:46 EST

Nkarta to Participate in March Investor Conferences

NKTXNkarta2026-06-25 13:46 EST

Nkarta to Participate in Needham Virtual Healthcare Conference

NKTXNkarta2026-06-25 13:46 EST

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

View all latest news

Nkarta

Nkarta is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

NKTXNkarta2026-06-26 12:02 EST

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

NKTXNkarta2026-06-26 12:02 EST

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

NKTXNkarta2026-06-26 12:02 EST

Nkarta to Participate in a September Investor Conference

NKTXNkarta2026-06-26 12:02 EST

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

NKTXNkarta2026-06-26 12:02 EST

Nkarta to Participate in November Investor Conferences

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States